 This study demonstrates the feasibility of using a 384 well plate format for testing the effectiveness of compounds in treating cystic fibrosis, CF. The researchers used a novel assay call for skull in induced swelling, FIS, which measures the ability of compounds to restore normal levels of CFTR protein in organoids derived from patients with the W1282x, W1282x CFTR nonsense mutation. They found that four out of the five statins tested, mevastatin, loveastatin, simvastatin, and fluvastatin, were able to increase CFTR function in these organoids. These results suggest that statins could be used to treat CF in individuals with the W1282x, W1282x mutation. Further research will be needed to determine if these findings can be replicated in other populations of CF patients.